Glucocorticoid sparing effect of zoledronic acid in sarcoid hypercalcemia
- 19 July 2017
- journal article
- case report
- Published by Springer Nature in Archives of Osteoporosis
- Vol. 12 (1) , 68
Abstract
Glucocorticoids are regarded as first-line therapy in the management of hypercalcemia associated with sarcoidosis. However, prolonged glucocorticoid therapy leads to metabolic abnormalities, Cushingoid habitus, and impairment of bone health. This study demonstrates the efficacy and glucocorticoid-sparing effect of zoledronic acid in sarcoid hypercalcemia.Keywords
This publication has 13 references indexed in Scilit:
- Use of systemic glucocorticoids and the risk of major osteoporotic fractures in patients with sarcoidosisOsteoporosis International, 2017
- Vertebral sarcoidosis: Clinical and imaging findingsSeminars in Arthritis and Rheumatism, 2002
- Clinical impact of bone and calcium metabolism changes in sarcoidosisThorax, 1998
- Prevention of Corticosteroid-Induced Osteoporosis with Alendronate in Sarcoid PatientsCalcified Tissue International, 1997
- Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis.Annals of the Rheumatic Diseases, 1995
- Hypercalcaemia due to sarcoidosis corrects with bisphosphonate treatmentPostgraduate Medical Journal, 1986
- Isolation and Structural Identification of 1,25- Dihydroxyvitamin D3Produced by Cultured Alveolar Macrophages in Sarcoidosis*The Journal of Clinical Endocrinology & Metabolism, 1985
- Characterization of 1 alpha-hydroxylation of vitamin D3 sterols by cultured alveolar macrophages from patients with sarcoidosis.Journal of Experimental Medicine, 1985
- Bone resorption stimulated by elevated serum 1,25-(OH)2-vitamin D concentrations in healthy menKidney International, 1983
- Evidence that Increased Circulating 1α,25-Dihydroxyvitamin D is the Probable Cause for Abnormal Calcium Metabolism in SarcoidosisJournal of Clinical Investigation, 1979